Accepted at 10:58 a.m. Jul, 19, 2024 by Cameron
Author: lawsonspence
Related Note: 1488768067383
Rationale for change

Leads to a more conceptual understanding of why these drugs work. Must realize this to answer the UWORLD question. Only 29% of people got the answer correct. (60% pick that the drug reduces the conversion of factor X to Xa). This makes me think that the AnKing card for this is insufficient in truly understanding the mechanism for these drugs.

Might help to include more info in the extra section ?
Source: UWorld - Step 1 14741

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step3_v12::#OME::Intern_Content::Common_Medical_Problems::AFib #AK_Step1_v12::#B&B::16_Neuro::03_Neurovascular_Disorders::06_Treatment_of_TIA/Stroke #AK_Step1_v12::#UWorld::Step::2133 #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::09_Factor_Xa_Inhibitors_(Apixaban/Rivaroxaban/Edoxaban) #AK_Step1_v12::#UWorld::Step::15390 #AK_Step1_v12::#UWorld::Step::11731 #AK_Step2_v12::#UWorld::Step::4649 #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step2_v12::Original_decks::Dorian::im::uw::cardio #AK_Step1_v12::#UWorld::Step::14741 #AK_Step2_v12::#UWorld::Step::6881 #AK_Step2_v12::#AMBOSS::tsaX9N #AK_Step1_v12::#UWorld::COMLEX::25920 #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::02_DirectThrombinInhibitors_DirectFactorXaInhibitors #AK_Step2_v12::#Resources_by_rotation::IM::uw::cardio::cardio_dorian #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#AMBOSS #AK_Step2_v12::#UWorld::COMLEX::101431 #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Low/HighYield::3-HighYield-temporary #AK_Step1_v12::#UWorld::COMLEX::25242 #AK_Step1_v12::#FirstAid::05_Pharm::04_Miscellaneous::01_Drug_names #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Factor_Xa_Inhibitors #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants #AK_Step1_v12::#AMBOSS::VkaG5k #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step2_v12::#B&B::14_Pulmonary_Critical_Care::03_Other::02_DVT_and_Pulmonary_Embolism #AK_Step2_v12::#SketchyIM::01_Cardiology::05_Blood_Vessel_Disease::01_DVT_SOAP #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#UWorld::COMLEX::26286 #AK_Step1_v12::#UWorld::COMLEX::25629